我们创建了荷兰版的巴黎觉醒障碍严重程度量表(PADSS),评估过去一年(PADSS年)的非快速眼动(NREM)失眠症症状。该问卷先前已在患有睡眠行走和/或睡眠恐怖(SW/ST)的患者中得到验证。我们在SW/ST患者中验证了问卷,在更广泛的人群中,包括有混乱性觉醒的患者,合并症,和药物使用者(“其他NREM失眠症”)。此外,我们介绍了一个涵盖过去一个月(PADSS-month)的版本,具有评估症状演变和治疗反应的潜在目的。
我们比较了54例SW/ST患者的PADSS评分,34个年龄匹配的对照,和23例其他NREM失眠症患者。我们评估了辨别能力,内部一致性,并构建效度。此外,我们评估了PADSS月的测试-重测可靠性和治疗反应。
健康对照得分显著低于两个患者组。我们发现了出色的诊断准确性(PADSS-年0.990,PADSS-月0.987的曲线下面积)和可接受的内部一致性。探索性因素分析确定了3个组成部分:“床外行为,在床上/周围的“\”行为,“和”暴力行为,“与前2个因素反映了SW和ST之间的区别。PADSS月显示出可接受的重测可靠性(0.75)。此外,药物和/或行为治疗后,PADSS-月显着降低。这种变化与护理人员的临床印象相关,这意味着PADSS月对治疗效果敏感。
荷兰的PADSS问卷可以用作广泛的NREM失眠症患者人群的筛查工具。不仅SW/ST。此外,我们验证了PADSS月版本,以评估症状的演变和治疗效果.
vanMierloP,HermansL,ArnulfI,PijpersA,OvereemS,1年和1个月版本的非快速眼动睡眠障碍严重程度量表的荷兰语翻译的验证。JClinSleepMed.2022年;18(4):1135-1143。
We created a Dutch version of the Paris Arousal Disorders Severity Scale (PADSS), which assesses non-rapid eye movement (NREM) parasomnia symptoms over the past year (PADSS-year). This questionnaire was previously validated in patients with sleep walking and/or sleep terrors (SW/ST). We validated the questionnaire in SW/ST patients, and in a broader population, including patients with confusional arousals, comorbidities, and medication users (\"other NREM parasomnias\"). Furthermore, we introduced a version covering the past month (PADSS-month), with the potential purpose of evaluating symptom evolution and treatment response.
We compared PADSS scores among 54 SW/ST patients, 34 age-matched controls, and 23 patients with other NREM parasomnias. We evaluated discriminative capacity, internal consistency, and construct validity. Furthermore, we assessed the test-retest reliability and treatment response of PADSS-month.
Healthy controls scored significantly lower than both patient groups. We found an excellent diagnostic accuracy (area under the curve PADSS-year 0.990, PADSS-month 0.987) and an acceptable internal consistency. Exploratory factor analysis identified 3 components: \"behaviors outside the bed,\" \"behaviors in/around the bed,\" and \"violent behaviors,\" with the former 2 factors reflecting the distinction between SW and ST. PADSS-month showed an acceptable test-retest reliability (0.75). Additionally, PADSS-month significantly decreased after pharmaceutical and/or behavioral treatment. This change was correlated with the clinical impression of the caregiver, implying that PADSS-month is sensitive to treatment effects.
The Dutch PADSS questionnaire can be used as a screening tool in a broad population of patients with NREM parasomnia, not only SW/ST. Furthermore, we validated a PADSS-month version to assess the evolution of symptoms and treatment effect.
van Mierlo P, Hermans L, Arnulf I, Pijpers A, Overeem S, van Gilst M. Validation of the Dutch translation of the Paris Arousal Disorders Severity Scale for non-REM parasomnias in a 1-year and 1-month version. J Clin Sleep Med. 2022;18(4):1135-1143.